Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity
| Status: | Recruiting |
|---|---|
| Conditions: | Obesity Weight Loss, Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/1/2018 |
| Start Date: | August 2016 |
| End Date: | December 2018 |
| Contact: | Pam Bunner |
| Email: | bunnerp@wvumedicine.org |
| Phone: | 304-598-4511 |
Patients receiving acyclovir as standard of care will be enrolled into this study. The
currently recommended dosing strategy at our institution for obese patients is to receive
intravenous acyclovir dosed per an adjusted body weight [IBW + 0.4(TBW-IBW)]. They will have
blood drawn once prior to the first dose of acyclovir and 10 times thereafter, over a total
time period of 12 hours. These patients will already be hospitalized for other reasons, and
will not be required to make additional trips to the hospital. A total of approximately 4-5
tablespoons of blood will be drawn for this study. Ten obese patients and 10 matched control
(non-obese) patients will be enrolled.
currently recommended dosing strategy at our institution for obese patients is to receive
intravenous acyclovir dosed per an adjusted body weight [IBW + 0.4(TBW-IBW)]. They will have
blood drawn once prior to the first dose of acyclovir and 10 times thereafter, over a total
time period of 12 hours. These patients will already be hospitalized for other reasons, and
will not be required to make additional trips to the hospital. A total of approximately 4-5
tablespoons of blood will be drawn for this study. Ten obese patients and 10 matched control
(non-obese) patients will be enrolled.
Inclusion Criteria:
- Age ≥18 years of age
- Receiving intravenous acyclovir 5 mg/kg (TBW for normal weight patients and ABW40 for
obese patients) as part of their routine care
- Weight > 190% of ideal body weight (IBW) for "obese" patients or weight 80-120% of IBW
for matched control patients.
Exclusion Criteria:
- Receipt of acyclovir or a pro-drug of acyclovir (valacyclovir, ganciclovir,
valganciclovir, famciclovir) in the prior 24 hours
- Serum creatinine >1.5 mg/dL
- Hypersensitivity to acyclovir
- Patients requiring ventilator support or vasopressors in the prior 24 hours
- Receipt of probenecid, mycophenolate, tenofovir, or zidovudine in the prior 7 days
- Significant anatomical deformities that influence body habitus (i.e. amputation)
- Prior inclusion in this study
We found this trial at
1
site
1 Medical Center Drive
Morgantown, West Virginia 26506
Morgantown, West Virginia 26506
304-598-4800
Phone: 304-598-4511
West Virginia University Hospitals Inc. WVU Healthcare is two corporations, University Health Associates and WVU...
Click here to add this to my saved trials
